Treatment of Locally Advanced Pancreatic Cancer

Slides:



Advertisements
Similar presentations
Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.
Advertisements

Saint Agnes Medical Center Oncology Symposium October 15, 2011 Neoadjuvant, Adjuvant and Palliative Management Marshall Flam, MD Hematology, Oncology Medical.
This house believes that FOLFIRINOX is the best treatment for patients with metastatic pancreatic adenocarcinoma Pro Marc YCHOU Montpellier.
Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.
Discussant: M Ducreux, MD, PhD Institut Gustave Roussy, Villejuif France TH-302 plus Gemcitabine vs. Gemcitabine in Patients with Untreated Advanced Pancreatic.
Dr Marco Matos Medical Oncologist Gold Coast Cancer Care, Gold Coast University Hospital and, Pacific Private Oncology Group.
Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.
A cura di Filippo de Marinis
A Single-Arm Phase IIIb Study of Pertuzumab and Trastuzumab with a Taxane as First-Line Therapy for Patients with HER2-Positive Advanced Breast Cancer.
Bladder Cancer: A New Era in Treatment
The Nurse View: Management of Pancreatic Cancer
What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard
Presented By Luca Malorni at 2017 ASCO Annual Meeting
LUCIE Localised Urothelial Carcinoma Immuno-oncology Evaluation Randomised Phase II trial, evaluating safety and efficacy of a combination therapy of.
New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application.
Endocrine Combinations in HR-Positive MBC: The Future Is Now
The Nurse View.
SAVOR-TIMI 53 Summary SAVOR-TIMI 53: Primary End Point of CV Death, MI, Ischemic Stroke.
A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer
PRODIGE 24/CCTG PA.6: Phase III Trial of Adjuvant mFOLFIRINOX vs Gemcitabine in Patients With Resected Pancreatic Ductal Adenocarcinoma CCO Independent.
Ospedale Misericordia, Grosseto
Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.
Her2-positive breast cancer: updating current best practice
Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.
Overall Program Goals. Overall Program Goals Current Approaches.
Metastatic Renal Cell Carcinoma
Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?
Activity Goals. Activity Goals Discussion Topics.
Program Goals. The Role of Chemotherapy in Improving Quality of Life in Advanced NSCLC.
Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams
Locally Advanced NSCLC Implementing Innovation
Supplemental Figure 1: Kaplan-Meier Curves of overall survival based on clinical stage at presentation and treatment modality Kaplan-Meier analyses depicting.
Managing gBRCA-Positive Metastatic Breast Cancer
Moving Prostate Cancer Care Forward: Putting Lessons From New Orleans and Chicago Into Practice.
Jordan Berlin Co-Director, GI Oncology Program
PCSK9 Inhibitors and Cardiovascular Outcomes
Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.
Oral Anticoagulation in AF
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Emerging Frontline Treatments for Patients With Hodgkin Lymphoma
Advancing the Treatment of IBD With Biologics
Advancing Care Across the Spectrum of Pancreatic Cancer
Nurse View: Practice Pearls in Advanced Pancreatic Adenocarcinoma
Patient-Centered Management in Pancreatic Cancer
Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib.
Treating CD30-Expressing Cutaneous T-Cell Lymphoma
Program Goals Overview Is NEDA a Reasonable Target?
Locally Advanced Lung Cancer
Hormone Receptor-Positive Advanced Breast Cancer Introduction
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Management of Advanced Pancreatic Adenocarcinoma
Are We Making Progress in the Management of Huntington Disease?
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
LV5FU2-cisplatin followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Preliminary results of a randomized phase III trial (FFCD.
Preparing for Checkpoint Inhibitors in Breast Cancer
CoPrincipal Investigators
Introduction. Emerging Treatments for Thrombocytopenia in Adults With CLD Requiring Elective Invasive Procedures.
Assessing the Burden of Hyperkalemia
Case Studies in Locally Advanced Pancreatic Cancer
Program Goals Overview Is NEDA a Reasonable Target?
Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.
Lo sviuppo clinico di nab-paclitaxel Lo studio APACT
Assessing the Burden of Hyperkalemia
Taking a Closer Look at Recurrent/Metastatic SCCHN
Real-World Evidence.
A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung.
Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.
A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an.
Uncovering the Right Sequence
Presentation transcript:

Treatment of Locally Advanced Pancreatic Cancer

Resectability of Pancreatic Adenocarcinoma at Diagnosis

Overview of Discussion

Phase 3 PRODIGE 24/CCTG PA.6 Trial Study Design

PRODIGE 24/CCTG PA.6 Trial Efficacy

PRODIGE 24/CCTG PA.6 Trial Disease-Free Survival

PRODIGE 24/CCTG PA.6 Trial Overall Survival

Phase 2 LAPACT Trial Study Design

LAPACT Trial Efficacy

Strengths and Limitations of the LAPACT Trial

Phase 3 LAP07 Trial Study Design

LAP07 Trial Efficacy in Gemcitabine-Only Arm

Phase 2 SCALOP Trial Study Design

SCALOP Trial Efficacy (Long-Term Follow-Up)

LAPACT Trial Best Response to Induction

LAPACT Trial Best Change From Baseline in Target Lesions

LAPACT Trial PFS and OS Kaplan-Meier Curves

LAPACT Trial Quality of Life During Induction

Summary of Clinical Trials Assessing Induction or Neoadjuvant Chemotherapy in LAPC

Phase 3 PREOPANC-1 Trial Study Design

PREOPANC-1 Trial Efficacy

PREOPANC-1 Trial Overall Survival in Intention to Treat Population

PREOPANC-1 Trial Overall Survival After R0/R1 Resection

PREOPANC-1 Trial Safety

LAPACT Trial Safety

PRODIGE Trial Key Takeaway

Emerging Role for Stereotactic Body Radiation Therapy in LAPC

New Standard of Care: Genetic Profiling in Pancreatic Cancer

ASCO® Guidelines for Potentially Curable Localized Pancreatic Adenocarcinoma

PRODIGE 24/CCTG PA.6 Trial Planned Dose Reduction of Irinotecan

PRODIGE 24/CCTG PA.6 Trial Adverse Events

LAPACT Trial–Toxicity Further Analysis

LAPACT Trial EORTC Quality-of-Life Scores (QLQ-C30)

Patient’s Overall Global Health With nab-Paclitaxel and Gemcitabine

Take-Home Points

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.